Novelty Nobility Inc.
PrivateLast Round
Series C
Nov 11, 2024
Est. Valuation
$89.74M
Total Funding Raised
$53.27M
Company Overview
Novelty Nobility Inc. operates in Healthcare & Life Sciences and is based in Seongnam-si. Its latest recorded funding round was a Series C round in November 2024.
Novelty Nobility Inc. is a biotechnology company that specializes in the design, discovery, and development of next-generation antibody therapeutics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates for oncology and immunology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Novelty Nobility Inc. Comparables
Compare Novelty Nobility Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Aimed Bio Inc. | 86% | |
| Pinotbio | 84% | |
| MabTics Co., Ltd. | 82% |
For institutional investors. Book with your work email.
Novelty Nobility Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Nov 11, 2024 | ||||
| Series B | May 16, 2022 | ||||
| VC Round | Mar 1, 2021 | ||||
| Series A | Jan 31, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Novelty Nobility Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| KDB Capital Corp | Series C |
| K2 Investment Partners | VC Round |
| Shinhan Venture Investment | Series C, Series A |
| SL Investment | Series B, Series C |
| Ulmus Investment | Series A |
| QUAD Investment Management | Series A |
| NH Investment & Securities | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 10, 2024
Grew 30% QoQ from 10 to 13 employees.
- May 16, 2022
$27M round with participation from NH Investment & Securities.
For institutional investors. Book with your work email.
Novelty Nobility Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Novelty Nobility Inc.'s valuation, stock price, and market status.
Is Novelty Nobility Inc. a public or private company?
Novelty Nobility Inc. is a private company.
What is the current stock price of Novelty Nobility Inc.?
Novelty Nobility Inc. is a private company, so its shares have no public market price. Caplight tracks Novelty Nobility Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Novelty Nobility Inc. worth (valuation)?
Novelty Nobility Inc.'s valuation is estimated at $89.7M based on funding round data.
Can I buy Novelty Nobility Inc. stock?
Novelty Nobility Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Novelty Nobility Inc.'s last funding round?
Novelty Nobility Inc.'s most recent funding round was Series C on November 11, 2024.
Who are the main investors in Novelty Nobility Inc.?
Key investors in Novelty Nobility Inc. include KDB Capital Corp, K2 Investment Partners, Shinhan Venture Investment, SL Investment, Ulmus Investment.
Will Novelty Nobility Inc. IPO soon?
No public IPO plans have been announced for Novelty Nobility Inc..
How can I track Novelty Nobility Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Novelty Nobility Inc.'s shares on secondary markets.